This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dose (10mg or 15mg).
English speaking adults between ages 18 and 65
Diagnosis of DSM5 AUD, severe
Completion of inpatient withdrawal management (i.e. "detox") for AUD within 90 days of enrollment
Amenable to attending all psychotherapy and study visits at BWH CCI
None